THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL

The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD20 (BCD-020, Acellbia®) that is a biosimilar of rituximab (RTM; MabThera®, F. Hoffmann-La Roche Ltd., Switzerland). In recent years, there has been evidence that RTM can be used at lower doses than th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: E. L. Nasonov, V. I. Mazurov, E. V. Zonova, L. A. Knyazeva, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, Yu. S. Shapovalova, E. P. Ilivanova, D. G. Krechikova, N. A. Petrochenkova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, A. F. Davydova, N. A. Eremina, E. V. Zemerova, T. B. Ivanova, A. A. Kastanayan, T. G. Pokrovskaya, S. A. Smakotina, E. A. Smolyarchuk, A. V. Artemyeva, R. A. Ivanov, Yu. V. Usacheva, E. V. Chernyaeva
Formato: Artigo
Idioma:Russo
Publicado em: IMA-PRESS LLC 2017-09-01
Colecção:Научно-практическая ревматология
Assuntos:
rheumatoid arthritis
rituximab
acellbia®
mabthera®
Acesso em linha:https://rsp.mediar-press.net/rsp/article/view/2407
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados